The Globe and Mail reports in its Thursday, Feb. 15, edition that RBC Capital analyst Irene Nattel has lowered her recommendation for Neighbourly Pharmacy to "sector perform" from "outperform." The Globe's David Leeder writes that Ms. Nattel slashed her share target by $7.50 to $18.50. Analysts on average target the shares at $19.29. Ms. Nattel issued her rating downgrade following the release of its third quarter 2024 results and ahead of its privatization in mid-March. Ms. Nattel says in a note, "While underlying operations are delivering solid and inline results, higher interest rates and the impact on cadence of M&A and valuation metrics for growth-by-acquisition names result in sharply moderated forecasts, target price." The Globe reported on June 13 that Desjardins Securities analyst Chris Li was sticking with his "hold" call on Neighbourly, which could then be had for $18.50. The Globe reported on July 14 that Ms. Nattel had reaffirmed her "outperform" recommendation for Neighbourly Pharmacy. The shares were then worth $15.45. The Globe reported on Jan. 17 that National Bank Financial analyst Zachary Evershed had moved Neighbourly Pharmacy to "tender" from "sector perform." It was then worth $18.27.